LAWRENCE, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. announces that Loraine V. Upham will join the team to lead the US operations and drug development effort for the diabetes portfolio. Formerly of Eli Lilly and Merck and Company, Upham brings both large pharmaceutical experience and private development stage company experience to the Boston Therapeutics team.
“We are pleased to have Lori join the US team, allowing us to expand the Boston Therapeutics global foot print. Her energy and commitment to the development and commercial success of our metabolic, diabetes and prediabetes portfolio in the US and abroad will join our growing Asia market presence this coming year as we establish ourselves for partnering and expansion in the US,” explains CEO, Carl Rausch. “Her experience and enthusiasm will fit with our global clinical plans as we commence clinical trials in the US. We can now leverage the China and Asia effort with the resources of a fully integrated global company.”
Upham co-founded CureDM in 2004, raised private capital, formed partnerships and helped drive the HIP2B peptide product development from just an idea to its current Phase 2-ready status. “I am honored to be a part of the Boston Therapeutics team. It provides a platform for the development of our existing compounds and other novel treatments that fit the strategic profile of changing the global economic impact of diabetes and its costly complications. A recent report entitled, ‘Economic Implications of Improving Type 2 Diabetes Management in China’ really underscores the worldwide importance and opportunity to make a difference with innovations like ours.”
Upham will report directly to CEO, Carl Rausch, and work closely with investment bank operations and US based partners to support operations in the US.
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) is an innovator in design, development and commercialization of compounds to treat diabetes and diabetes related complications.
